Introduction
For advanced prostate cancer, androgen-deprivation therapy (ADT) is the mainstay of treatment and despite initial responses essentially all patients progress to so-called 'castration resistance' [1, 2] . Two recently developed, androgen-receptor (AR) axis targeting agents (abiraterone and enzalutamide) improve overall survival in metastatic castration-resistant prostate cancer (mCRPC) [3] [4] [5] . The outcome differences due to these so-called next-generation ADT agents changed the treatment landscape of mCRPC [6] [7] [8] . Unfortunately, not all patients benefit from nextgeneration ADT and whilst several underlying mechanisms have been delineated [9] [10] [11] there is currently no predictive biomarker to stratify patients with mCRPC to the appropriate therapy.
Detection of the AR splice variant 7 (AR-V7) is a promising biomarker for therapy selection in mCRPC (Fig. 1A ,B [3, 10] ). The AR-V7 splice-variant encodes a truncated, constitutively active version of the AR that also lacks the ligand-binding domain encoded by exons 4-8 ( Fig. 1C) , which renders the protein invulnerable to essentially all AR-axis-targeting agents [3] . Antonarakis et al. [10] showed that detection of AR-V7 mRNA in circulating tumour cells (CTC) of patients with mCRPC was associated with non-response to next-generation ADT. Several subsequent confirmatory studies followed [3, [12] [13] [14] and importantly the response rates to taxane-based chemotherapy showed no significant difference between AR-V7-positive vs -negative patients with mCRPC [3, 10, [12] [13] [14] [15] [16] . These findings collectively argue for AR-V7 as a potential treatment selection biomarker in the setting of mCRPC (Fig. 1A) . However, recent data argue otherwise [12, 17] . Specifically, a non-negligible subset of~20% of patients benefit from abiraterone and/or enzalutamide treatment despite expression of AR-V7 [12] . These findings were in stark contrast to the initial data by Antonarakis et al. [10] , where none of the AR-V7-positive patients responded to abiraterone or enzalutamide. In conjunction, the newer evidence questions the current dogma to withhold an otherwise safe therapeutic option to patients based on their AR-V7-CTC status.
It is understandable that these largely discrepant data on predictive properties of AR-V7 sparked a scientific debate with translational [18] [19] [20] , clinical [21] [22] [23] [24] , and economic relevance [7, 25] . Such discrepancies in evidence-based medicine warrant careful comparison of the underlying applied methodologies. Interestingly, both groups [3, 10, 26] applied identical upstream approaches for CTC enrichment, mRNA isolation and complementary DNA (cDNA) synthesis (Fig. 1C) . However, in contrast to Antonarakis et al. [10] , who applied a SYBR Green quantitative PCR (qPCR) chemistry, Steinestel et al. [3] employed a TaqMan qPCR chemistry for the detection of AR-V7 mRNA transcripts (Fig. 1C) . Given that SYBR Green-based and TaqMan-base detection systems have different sensitivities and specificities, the TaqMan assay could classify low-level AR-V7 as (false) positive. In other words, the paradoxical responses to nextgeneration ADT in AR-V7-mRNA-positive patients could be due to false-positive classification caused by differences in the detection system [21, 27] . To our knowledge a direct performance comparison of the two established AR-V7 mRNA detection systems has not been performed.
In order to dissect possible assay differences we compared analytical specificity, sensitivity and concordance of these two CTC-derived mRNA-based AR-V7 assays (Steinestel et al. [3] vs Antonarakis et al. [10) ]). The direct link between AR-V7 assay accuracy and the emerging clinical value as a biomarker underscores the importance of direct assay performance comparisons when assessing the relevance of a biomarker for patient care.
Material and Methods

Study Design and Ethics Approval
To compare the performance of two mRNA-based AR-V7 assays [3, 10, 12] , we used three independent approaches: (i) an in vivo comparison using cell lines with known AR-V7 status (specificity), (ii) sensitivity threshold determination using series dilution assays, and (iii) direct practical performance comparison in liquid biopsies from patients with castrationresistant prostatic adenocarcinoma (for inclusion criteria see Steinestel et al. [3] structure. Both assays span the exon junction between exon 3 and cryptic exon 3 of AR resulting in AR-V7 mRNA. The assays only differ in the primer design using either primers located within exon 3 and cryptic exon 3 [10] or an exon spanning forward primer, a reverse primer located in cryptic exon 3 and a hydrolysis probe located in between both primers [3] . (C) Pre-analytical steps of CTC enrichment, mRNA isolation and cDNA synthesis. Patient blood samples were collected in EDTA tubes and after isolation and enrichment of CTCs, mRNA was isolated and cDNA synthesised identical to prior reports (see methods).
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Cell Lines
Human prostate cancer cell lines 22Rv1, LNCaP, VCaP and PC-3, human clear cell renal cell lines CAKI-1 and CAKI-2 and human bladder cancer cell lines RT-4 and RT-112 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and we followed matching protocols for media preparations and culture at 37°C and 5% CO 2 . We purchased media, trypsin-EDTA, phosphatebuffered saline, fetal calf serum, and horse serum from PAA Laboratories (Pasching, Germany). We isolated total RNA from cell lines at~60-80% confluence using the RNeasy Mini kit (Qiagen, Hilden, Germany) and performed reverse transcription of 500 ng RNA into cDNA using the Quantitect Reverse Transcription Kit for cDNA synthesis with integrated removal of genomic DNA (gDNA) (Qiagen) using the following thermocycler protocol: 42°C for 2 min without gDNA wipeout, 42°C for 30 min with gDNA wipeout, 95°C for 3 min; cDNA was stored at À20°C.
Serial Dilution Assays
We used ascending concentrations of cDNA from the known AR-V7 expressing prostate cancer cell lines 22Rv1, VCaP and LNCaP [28] . All experiments were performed using appropriate positive-and negative-cDNA, as well as water controls. We performed qPCR reactions on ribosomal protein L37a (RPL37A), as a housekeeping gene control, to ensure cDNA integrity even in high dilutions (RPL37A primer sequences for TaqMan qPCR: Hs01102345_m1, (ThermoFisher Scientific, Waltham, MA, USA); for SYBR Green qPCR: for 3 0 -GTGGTTCCTGCATGAAGACAGTG-5 0 ; rev 3 0 -TTCTGATGGCGGACTTTACCG-5 0 ). All qPCR reactions were run on a QuantStudio 3 (ThermoFisher Scientific).
Patient Samples
We collected peripheral venous blood (5-10 mL) in EDTA blood collection tubes (Sarstedt, Nuernbrecht, Germany). Samples were processed within 4 h after blood drawing (Fig. 1C) . CTC enrichment, mRNA isolation and cDNA synthesis were identical for both assays and followed prior reports [3, [10] [11] [12] . For CTC enrichment and mRNA isolation we used the AdnaGen Prostate Cancer Select and Detect Kit, respectively (AdnaGen Qiagen, Hannover, Germany). Reverse transcription of mRNA into cDNA was achieved using the SensiScript RT kit (Qiagen) in a 20 lL reaction using the following thermocycler settings: 37°C for 60 min, 93°C for 5 min; cDNA was stored at À20°C. For determination of presence of CTCs we performed qPCR using a previously described kallikrein-related peptidase 3 (KLK3)-PSA TaqMan assay [3] . Of note, the number of CTCs per sample cannot be determined and a patient sample was classified as CTCpositive when displaying positive qPCR signals for KLK3-PSA and/or full length transcript of the AR (AR-FL). AR-V7 status was determined by custom-made TaqMan qPCR analysis along with TaqMan qPCR for housekeeping control genes 5 0 -aminolevulinate synthase 1 (ALAS1) and glucose 6-phosphate dehydrogenase (G6PD). Furthermore, we performed analysis of CTC-specific genes in 10 patient samples using the AdnaGen Prostate Cancer Detect kit containing multiplex PCR primers for detection of AR, KLK3-PSA, prostate-specific membrane antigen (PSMA), and epidermal growth factor receptor (EGFR) according to the manufacturers manual (AdnaGen Qiagen). PCR products of samples were run on a Bioanalyzer (Agilent, Santa Clara, CA, USA).
AR-V7 Detection
Both AR-V7 assays are mRNA-based and have been independently developed and previously published [1, 3, 10, 13, 14, 17] . Briefly, the 'Antonarakis assay' [10] refers to a SYBR green-based qPCR [1, [13] [14] [15] [16] , whereas the 'Steinestel assay' [3] refers to a TaqMan qPCR. The design is depicted in Fig. 1B and for both assays we used the originally published primers following the exact, previously published protocols:
SYBR Green qPCR
For the AR-V7 SYBR Green qPCR reaction, we used the Power SYBR Green Master Mix (ThermoFisher Scientific) and the following PCR protocol: 95°C 9 10 s, 58°C 9 30 s, and 72°C 9 30 s for 39 cycles along with melting curve analysis. SYBR Green qPCR runs were performed using a QuantStudio 3 qPCR cycler (ThermoFisher Scientific).
TaqMan qPCR
For the TaqMan assay we used the primers and hydrolysis probe along with the TaqMan Fast Advanced MasterMix (ThermoFisher Scientific) using the following protocol: 95°C 9 15 s, 60°C 9 60 s. TaqMan qPCR runs were performed using a QuantStudio 3 qPCR cycler (ThermoFisher Scientific). The qPCR chemistry differences between the two assays used in our study prompted us to define distinct threshold values for AR-V7 determination. For TaqMan qPCR the threshold value was set at cycle 45 considering a primer efficiency of about 90-110%. For the SYBR Green assay the threshold values were set at cycle 39; according to Antonarakis et al. [10] , no AR-V7 signal was detected after cycle 36.
Statistical Analysis
We compared assay specificity via analysis of AR-V7 expression in different genitourinary cancer cell lines of distinct tumour entities (prostate cancer, bladder cancer, renal cancer). Using dichotomous stratification of presence or absence of signals we determined cell lines being positive or negative for AR-V7 expression. Analytical sensitivity was defined as the lowest dilution, in which a cycle threshold (Ct) value was detected. We defined concordance of results by comparing parallel analysis of both assays in identical patient samples. Fig. 2A) . No AR-V7 expression was found in the prostate cancer cell line PC-3, clear cell RCC, and bladder cancer cell lines. These results show that both assays are performing appropriately and specifically.
Results
Specificity for AR-V7 Detection in Genitourinary
Cancer Cell Lines When analysing a set of eight genitourinary cancer cell lines (four prostate cancer, two clear cell RCC, and two bladder cancer) with either SYBR Green or TaqMan qPCR, we uniformly detected AR-V7 in prostate cancer cell lines 22Rv1, LNCaP and VCaP (
Analytical Sensitivity Determination Using cDNA Dilution Series
Next, we compared the analytical sensitivity to determine the diagnostic threshold of both assays. Therefore, we performed qPCR using cDNA dilutions of 22Rv1, VCaP and LNCaP cells as template. For 22Rv1 and VCaP cDNA, both assays detected expression of AR-V7 up to a 10 000-fold dilution (Fig. 2B) of the original cDNA, corresponding to~5 pg of input RNA or one single cell as the formal detection limit. For LNCaP cDNA, both assays detected expression of AR-V7 up to a 1 000-fold dilution or 50 pg of input RNA equivalent to 1-10 cells as the formal detection limit, which is in line with prior validations [1] . Comparison with RPL37A, as a housekeeping control, showed integrity of cDNA even in high dilutions (Fig. 2C) .
Concordance of Both Assays in Clinical Patient Samples
In all, 10 clinical samples were analysed for presence of CTCs using the AdnaGen Prostate Cancer Detect kit for expression analysis of KLK3-PSA, PSMA or EGFR (Fig. 3A) . Two samples were found to be CTC-negative, whereas eight samples showed expression of at least one of the CTC markers implying presence of CTCs (classified as CTCpositive, see methods). Furthermore, by running a PCR using AR-V7 and AR-FL specific forward and reverse primers of both assays, we were able to concordantly detect AR-FL, as well as AR-V7, in eight out of 10 and four out of 10 patient samples, respectively (Fig. 3A) .
Subsequently, we performed parallel AR-V7 detection of 32 clinical samples using both TaqMan qPCR, as well as SYBR Green qPCR detection. Both detection systems showed identical results for AR-V7 status in all 32 clinical samples (Fig. 3B) . Perfect concordance in these 32 samples confirms substantial equivalence of both assays. Notably, the subgroup of 18 patients identified as AR-V7 positive (by both assays) included three samples from patients that showed clinical benefit from next-generation ADT despite being AR-V7 positive [12, 13] . These findings underscore that differences between the two assays can be safely excluded as the underlying reason for the unexpected responses to nextgeneration anti-androgen therapy in a subset of patients with AR-V7-positive CTCs.
Discussion
Here, we report a performance comparison of two mRNAbased AR-V7 detection assays based on either SYBR Green or TaqMan chemistry. By showing identical specificity using cell lines, identical sensitivity using serial dilution assays, and perfect concordance using 32 CTC-derived samples from patients with prostate cancer, our present findings are relevant from a technical, clinical and overall utility perspective.
From a technical perspective, a direct comparison between two assays can serve as a surrogate for assay validity (i.e. determining whether the assay is measuring what it is supposed to measure). It is important to point out that both assays rely on identical pre-analytical steps, in particular the identical kits for CTC isolation, and mRNA capture (AdnaGen) [3, 10, 12, 21, 27] . Both assays detect processed (spliced) AR-V7 mRNA and there are only two technical differences: (i) the applied PCR chemistry (SYBR Green vs TaqMan) and (ii) the related primer design [3, 10, 17] . The RT-PCR/SYBR green assay contains primers located in exon 3 and cryptic exon 3, respectively, resulting in an exon junction spanning PCR product. The TaqMan approach consists of an exon junction spanning forward primer, a reverse primer located within cryptic exon 3 and, additionally, a hydrolysis probe located between both primers [3, 17] . The TaqMan assay using three oligonucleotides is regarded to be more specific compared to the two oligonucleotide based SYBR Green chemistry. Thus, we wanted to determine whether assays with different designs and chemistries can detect lower levels of AR-V7 mRNA. These findings are relevant because the more sensitive assay could result in falsepositive classification. However, we show that both assays have identical performance measures and thereby establish that both detection methods are technically valid in determining the AR-V7 status in CTCs. Given the current lack of a CTC-based AR-V7 detection 'gold standard', it is noteworthy that a broader comparison of distinct detection technologies is urgently needed however challenging given the 222 © 2018 The Authors BJU International © 2018 BJU International limited amount of isolated CTCs per patient. Similarly, the limited amount of CTCs/nucleic acids per patient currently also preclude our ability to compare performance with other AR-V7 assay detection methods (e.g. protein-level, in situ hybridisation [20, [29] [30] [31] ) or more comprehensive assessments (e.g. next-generation sequencing [32] ).
Clinically, our present results are meaningful because assay differences have been repeatedly quoted as an underlying reason for unexpected responses to next-generation antiandrogen therapy in AR-V7-positive patients [21, 27] . Briefly, we have reported that a subset of patients may benefit from abiraterone and/or enzalutamide treatment despite expression of AR-V7 [12] . In our series of 21 AR-V7-positive patients, we detected a subset of four patients (~20%) showing a PSA level decrease of ≥50% upon abiraterone treatment [12] . Our report of unexpected AR-V7-positive responders clearly questioned the prevailing dogma [10, 14, 26] . Importantly, when carefully reviewing published data it should have been clear that a subset of AR-V7-positive patients would benefit from next-generation ADT [17] . Nonetheless, our detection method has been portrayed as potentially flawed [21, 27] . We now show that these methodological criticisms were not based on experimental data. By excluding assay differences as the underlying reason for unexpected AR-V7-positive responders we eliminate these statements as speculative [17] . Furthermore, by establishing that both assays are valid in determining the AR-V7 status, including those patients responding to next-generation ADT, is an important milestone towards assessment of the true clinical utility of AR-V7 as a biomarker. The utility of AR-V7 as a biomarker in the setting of CRCP will require further clarification. As with other biomarkers, determination of the true clinical utility unfolds in phases [33] . Early-phase studies suggested that AR-V7 is 100% predictive of non-response to next-generation ADT [10] and whilst several groups confirmed predictive properties [3, 14, 26] , the mid-phase is characterised by alternative techniques, the need for carefully designed clinical trials, and demonstrating outcome differences [3, 13, 14, 26, 28, 34] . However, the decision to use AR-V7 in clinical practice (latephase) will be based on the expectation that testing will have a positive net health impact for patients with prostate cancer [25] . In prior publications, the fact that AR-V7 expression is not associated with resistance to taxane-based chemotherapy has been employed to justify AR-V7 testing [14, 15, 34] . However, in our opinion the more meaningful comparison is that of response rates to the two therapeutic alternatives and projecting this on the tested population. Antonarakis et al. [26] recently reported that the response rate in AR-V7-positive patients to next-generation ADT is~27% (four of 15 patients), whereas the response rate to chemotherapy in AR-V7-positive patients is~36% (19of 53 patients) [16] . At first glance these numbers suggest a difference of~9%; however, when applied to all tested patients, the net benefit from testing can be estimated around~1.5% [22] , which is considerably lower than currently portrayed. These data indicate the need to revise prior cost saving calculations [25] and to have more realistic expectations when reviewing recent prospective trials [35] [36] [37] [38] . These considerations are directly linked to AR-V7 detection methods because ultimately both assays could for example be too sensitive and detect AR-V7 levels below therapeutically relevant levels. For example, the successful Androgen Receptor Modulation Optimized for Response (ARMOR) II study used protein-based AR-V7 detection [36, 39] , whereas more recent data from the less promising ARMOR III study used mRNA-based AR-V7 detection [37] , supporting that detection at the protein level may better reflect biological function [13, 20] . We consider experimental examination of seemingly discrepant data essential for the ongoing debate regarding the predictive properties of AR-V7 [17, 21, 27] . In particular, we caution to not abandon AR-V7 testing without careful and comprehensive review of all available data. Clearly there is a need for alternative therapies [13, 17, 21, 22, 27, 37, 40] and more integrated genomic approaches [2, 41, 42] ; however, the expected measurable biomarker benefit, even if smaller than anticipated, should be recognised in the context of an aggressive clinical course of AR-V7-positive patients with prostate cancer [14, 37] . Thus, teasing apart the prognostic and predictive properties of AR-V7 positivity will require carefully designed clinical studies and reliable biomarker assays including a broader comparison of and between different methods.
In summary, we present a comparison of two mRNA-based detection technologies for AR-V7 from CTCs. We demonstrate identical performance metrics, including determination of AR-V7 positivity, by both assays, in patients who responded to next-generation ADT. Exclusion of assayspecific differences as the underlying reason for the unexpected responses, underscores that AR-V7-positive patients should not be systematically denied an otherwise safe and effective treatment. Given that the AR-V7 status in CTCs cannot entirely predict non-response, the most meaningful setting and the true clinical utility of AR-V7 mRNA testing remains to be determined.
Conclusion
Here, we report the results of a performance comparison of two AR-V7 mRNA assays with seemingly distinct predictive properties to next-generation ADT [10, 12, 27] . We demonstrate identical performance metrics and show that the detection of unexpected AR-V7-positive responders was not based on assay differences. These data strongly re-emphasise that AR-V7-positive patients should not be precluded from an otherwise safe medication.
